Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Polydeoxyribonucleotide Injection in the Treatment of Chronic Supraspinatus Tendinopathy : A Case-Controlled, Retrospective, Comparative Study With 6-Month Follow-Up (2017) |
Auteurs : | Young Chun Yoon ; Doo-Hyung Lee ; Michael Young Lee |
Type de document : | Article |
Dans : | Archives of Physical Medicine and Rehabilitation (2017/5, 2017) |
Article en page(s) : | pp. 874-880 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Rééducation et réadaptation |
Mots-clés: | Rotator cuff ; Coiffe des rotateurs ; Shoulder pain ; Scapulalgie ; Tendinopathy ; Tendinopathie |
Résumé : |
Objective To determine the efficacy of polydeoxyribonucleotide (PDRN) injection for rotator cuff disease (RCD). Design Case-controlled, retrospective, comparative study. Setting Outpatient clinic at a university-affiliated tertiary care hospital. Participants Patients (N=106) with chronic nontraumatic refractory RCD who were unresponsive to at least 1 month of conservative treatment: 55 patients received PDRN injection (PDRN group) and 51 continued conservative treatment (control group). Interventions Not applicable. Main Outcome Measures Shoulder Pain and Disability Index, score on a visual analog scale of the average shoulder pain level, number of analgesic ingestions per day, isometric strength of shoulder abductor, active range of motion (flexion, abduction, internal rotation, external rotation), and maximal tear size of tendon on ultrasonography at pretreatment and 3 and 6 months postinjection. Results There was no significant difference between the 2 groups in terms of age, sex, shoulder affected, duration of symptoms, and ultrasonographic findings at pretreatment. Compared with the control group, the treatment group showed a significant improvement in Shoulder Pain and Disability Index, visual analog scale score, and number of analgesic ingestions per day. However, there was no difference in isometric strength, active range of motion, and maximal tear size of tendon. No adverse events were reported. Conclusions To our knowledge, this is the first study to assess the efficacy of PDRN injection for patients with RCD. The PDRN injection group showed improvement in pain and subjective disability in patients with RCD and continued to show improvement for 3 months thereafter; the PDRN injection can be an optional treatment for patients with chronic RCD who show no response to other treatments. |
Disponible en ligne : | Oui |
En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S0003999316312874 |